Moore Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Moore Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-125,000	Closed	-$26.7M	–	652
2025 Q4	$26.7M	Buy	125,000 +35,000	+39%	+$7.23M	0.38%	59
2025 Q3	$17.9M	Sell	90,000 -30,000	-25%	-$5.6M	0.25%	90
2025 Q2	$20.7M	Buy	120,000 +30,000	+33%	+$4.89M	0.26%	80
2025 Q1	$14M	Buy	90,000 +70,000	+350%	+$10M	0.29%	70
2024 Q4	$2.75M	Sell	20,000 -20,000	-50%	-$2.63M	0.03%	297
2024 Q3	$5.97M	Buy	+40,000	New	+$5.4M	0.11%	200
2023 Q1	–	Sell	-20,000	Closed	-$2.44M	–	493
2022 Q4	$2.44M	Buy	+20,000	New	+$2.32M	0.06%	250
2020 Q1	–	Sell	-37,133	Closed	-$5.17M	–	170
2019 Q4	$5.17M	Buy	+37,133	New	+$4.13M	0.17%	136

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Moore Capital Management's ASND Position: Q1 2026 in Review

Moore Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 125,000 shares — an estimated $26.7M sold.

Moore Capital Management first reported a position in ASND in Q4 2019 and held it in 8 quarters. The position peaked at $26.7M in Q4 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Moore Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 125,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $26.7M.
Moore Capital Management first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 8 quarters.
Moore Capital Management's Ascendis Pharma A/S position peaked at $26.7M in Q4 2025.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.